Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Case report: effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis : a case series
Avtorji:ID Krhlikar, Nina (Avtor)
ID Tomšič, Matija (Avtor)
ID Jaki Mekjavić, Polona (Avtor)
ID Klobučar, Pia (Avtor)
ID Vidović Valentinčič, Nataša (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (4,01 MB)
MD5: 3F0B4A738BFFD5FB12FA2D6F336ECCEC
 
URL URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1509404/full
 
Jezik:Angleški jezik
Tipologija:1.03 - Drugi znanstveni članki
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Purpose: This study aimed to assess the efficacy of Janus kinase inhibitors (JAK-i) in the treatment of refractory isolated non-infectious uveitis. Case presentation: We examined a case series involving three patients with isolated non-infectious uveitis, who were managed between December 2019 and December 2023 at The Eye Hospital, University Medical Centre Ljubljana. The JAK-i therapy was initiated due to the patients’ unresponsiveness to disease-modifying antirheumatic drugs. Outcomes: In our case series, two patients presented with anterior and intermediate uveitis, one with posterior uveitis. None of the patients had any associated systemic disease. After the initiation of JAK-I therapy, all the patients achieved remission lasting for more than 1 year. No significant side effects were observed in any of the patients throughout a mean follow-up period of 31.6 months (range, 16–55 months). Conclusion: In this report, we present three cases of refractory isolated non-infectious uveitis successfully treated with JAK-i. This is the first report on the use of baricitinib and upadacitinib in this context. Our findings suggest that alternative use of JAK-i, apart from tofacitinib alone, may be an effective treatment option for such patients.
Ključne besede:JAK inhibitors, uveitis, biologics
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:7 str.
Številčenje:Vol. 16, [article no.] 1509404
PID:20.500.12556/DiRROS-24535 Novo okno
UDK:61
ISSN pri članku:1663-9812
DOI:10.3389/fphar.2025.1509404 Novo okno
COBISS.SI-ID:237141507 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 26. 5. 2025;
Datum objave v DiRROS:04.12.2025
Število ogledov:14
Število prenosov:6
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Frontiers in pharmacology
Skrajšan naslov:Front Pharmacol
Založnik:Frontiers Media
ISSN:1663-9812
COBISS.SI-ID:29551833 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0333-2019
Naslov:Očesne bolezni odraslih in otrok

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj